Ann W. Silk

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

33h-index5.9kcitations188works7.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(48), Cancer Immunotherapy and Biomarkers(47), Polyomavirus and related diseases(35), Immunotherapy and Immune Responses(29), Nonmelanoma Skin Cancer Studies(25)

Publications187 total

Response to Gao and Chen, “Comments on Akaike et al.’s ‘Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management’”
Journal of the American Academy of Dermatology·2026
Discordant circulating tumor DNA results favor multiple primary malignancies in patient with synchronous Merkel cell carcinoma tumors
JAAD Case Reports·2025Open Access
1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study
2025Open Access
1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial
2025Open Access
599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma
Regular and Young Investigator Award Abstracts·2025Open Access
Circulating Tumor DNA Predicts Response After Definitive Radiation Therapy for Merkel Cell Carcinoma
Advances in Radiation Oncology·2025Open Access
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management
Journal of the American Academy of Dermatology·2025
1669P Prognostic impact of organ-specific metastasis on survival in patients with Merkel cell carcinoma
Annals of Oncology·2025
LBA55 START-001: Initial phase II clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) β-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB)
Annals of Oncology·2025
62100 Extramammary Paget’s Disease of Extra-genital Origins: A Retrospective Cohort Study
Journal of the American Academy of Dermatology·2025
Chemosensitization is not associated with improved adjuvant radiation outcomes for cutaneous squamous cell carcinoma: A dual-center retrospective cohort study
Journal of the American Academy of Dermatology·2025
LBA56 ECOG-ACRIN EA6174: STAMP: Surgically treated adjuvant merkel cell carcinoma with pembrolizumab, a phase III trial
Annals of Oncology·2025· 2 cited
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
Journal of Clinical Oncology·2025· 2 cited
State-level trends and associated disparities in melanoma burden in the United States.
Journal of Clinical Oncology·2025
Comparison of surveillance circulating tumor DNA and Merkel polyomavirus antibody titer for detection of Merkel cell carcinoma recurrence.
Journal of Clinical Oncology·2025
Progression patterns and clinical outcomes after anti-PD-1 therapy failure in patients with cutaneous squamous cell carcinoma.
Journal of Clinical Oncology·2025
Role of high-dose interleukin-2 for melanoma in the age of cellular therapy
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Using oncolytic viruses to induce hyperacute rejection against cancer
Nature Reviews Clinical Oncology·2025· 1 cited
Association of cutaneous immune-related adverse events with improved overall survival among patients with cutaneous squamous cell carcinoma treated with palliative programmed death receptor-1 inhibition
Journal of the American Academy of Dermatology·2025
page 1 of 10Next →

Frequent Co-authors

Howard L. Kaufman(15), Andrew Zloza(11), Praveen K. Bommareddy(9), Janice M. Mehnert(8), Emily S. Ruiz(8), Chrysalyne D. Schmults(8), Janice M. Mehnert(7), Jyoti Malhotra(7), Glenn J. Hanna(7), Manisha Thakuria(6), Nicole R. LeBoeuf(5), Nancy Chan(5), Sunandana Chandra(5), Igor Puzanov(4), Michael P. Kane(4), Shridar Ganesan(4), Tracie Saunders(4), Jenna H. Newman(4), Daniel Medina(4), Sachin R. Jhawar(4)